Free Access
Neuropsychobiology 2005;51:214–225

On the Pharmacotherapy of Sleep Bruxism: Placebo-Controlled Polysomnographic and Psychometric Studies with Clonazepam

Saletu A.a · Parapatics S.b-d · Saletu B.b, d · Anderer P.b · Prause W.b · Putz H.d · Adelbauer J.d · Saletu-Zyhlarz G.M.b, d
Departments of aDental Medicine, bPsychiatry and cMedical Cybernetics and Artificial Intelligence, Medical University of Vienna, and dRudolfinerhaus, Vienna, Austria
email Corresponding Author

 goto top of outline Key Words

  • Sleep bruxism
  • Pharmacotherapy
  • Clonazepam
  • Polysomnography
  • Awakening quality
  • Thymopsyche
  • Noopsyche
  • Periodic limb movements
  • Respiratory variables
  • Arousals

 goto top of outline Abstract

Objectives: Sleep bruxism (SB) is a parasomnia defined as a stereotyped movement disorder characterized by grinding or clenching of the teeth during sleep. Pathophysiologically, SB is the result of biological and psychosocial influences. Treatment comprises behavioral, orthodontic and pharmacological interventions. While benzodiazepines and muscle relaxants have been reported by clinicians to reduce bruxism-related motor activity, placebo-controlled studies are lacking. Thus, the aim of the present study was to investigate the acute effects of clonazepam (Rivotril®) as compared with placebo, utilizing polysomnography and psychometry. Method: Ten drug-free outpatients (6 females, 4 males), aged 46.5 ± 13.1 years, suffering from SB (ICD-10: F45.8; ICSD: 306.8) and having been treated by bite splints were included in the trial. Comorbidity was high: 7 patients presented nonorganic insomnia related to adjustment or anxiety disorders (5 patients) or depression (2 patients); all patients had a concomitant movement disorder (6 restless legs syndrome, 4 periodic leg movement disorder). After one adaptation night, patients received placebo and 1 mg clonazepam 1/2 hour before lights out in a single-blind, nonrandomized study design. Objective sleep quality was determined by polysomnography, subjective sleep and awakening quality by rating scales, objective awakening quality by psychometric tests. Clinical evaluation was based on the Pittsburgh Sleep Quality Index (PSQI), the Zung Depression (SDS) and Anxiety (SAS) Scales, the Quality of Life Index, the Epworth Sleepiness Scale and the International Restless Legs Syndrome Study Group (IRLSSG) Scale. Results: On admission, SB patients exhibited deteriorated PSQI, SAS, SDS and IRLSSG measures. As compared with placebo, 1 mg clonazepam significantly improved the mean bruxism index from 9.3 to 6.3/h of sleep. Furthermore, it significantly improved the total sleep period, total sleep time, sleep efficiency, sleep latency and time awake during the total sleep period, and increased stage 2 sleep and movement time. Periodic leg movements decreased significantly, while the apnea index and apnea-hypopnea index increased marginally, but remained within normal limits. Subjective sleep quality improved as well, while in mood, performance and psychophysiology no changes were observed. Conclusion: Acute clonazepam therapy significantly improved not only the bruxism index but also objective and subjective sleep quality, with unchanged mood, performance and psychophysiological measures upon awakening, suggesting good tolerability of the drug.

Copyright © 2005 S. Karger AG, Basel

 goto top of outline References
  1. Diagnostic Classification Steering Committee, Thorpy MJ, chairman: International Classification of Sleep Disorders: Diagnostic and Coding Manual, Revised. Rochester, American Sleep Disorders Association, 1997, pp 182–185.
  2. World Health Organisation: International Classification of Diseases and Related Health Problems. Geneva, World Health Organisation, 1992.
  3. Glaros AG, Rao SM: Bruxism: A critical review. Psychol Bull 1977;84:767–781.
  4. Kristal L: Bruxism: An anxiety response to environmental stress; in Spielberger CD, Sarason IG (eds): Stress and Anxiety. Washington, Hemisphere, 1978, vol 5, pp 45–59.
  5. Harness DM, Peltier B: Comparison of MMPI scores with self-report of sleep disturbance and bruxism in the facial pain population. Cranio 1992;10:70–74.
  6. Biondi M, Picardi A: Temporomandibular joint pain-dysfunction syndrome and bruxism: Etiopathogenesis and treatment from a psychosomatic integrative viewpoint. Psychother Psychosom 1993;59:84–98.
  7. Hartmann E: Bruxism; in Kryger MH, Roth T, Dement WC (eds): Principles and Practice of Sleep Medicine. Philadelphia, WB Saunders Co, 1994, pp 598–604.
  8. Kampe T, Tagdae T, Bader G, Edman G, Karlsson S: Reported symptoms and clinical findings in a group of subjects with longstanding bruxing behaviour. J Oral Rehabil 1997;24:581–587.
  9. Pierce CJ, Chrisman K, Bennett ME, Close JM: Stress, anticipatory stress and psychologic measures related to sleep bruxism. J Orofac Pain 1995;9:51–56.
  10. Pingitore G, Chrobak V, Petrie J: The social and psychologic factors of bruxism. J Prosthet Dent 1991;65:443–446.
  11. Bader GG, Kampe T, Tagdae T, Karlsson S, Blomqvist M: Descriptive physiological data on a sleep bruxism population. Sleep 1997;20:982–990.
  12. Major M, Rompré PH, Guitard F, TenBokum L, O’Connors K, Nielsen TA, et al: A controlled daytime challenge of motor performance and vigilance in sleep bruxers. J Dent Res 1999;78:1754–1762.
  13. Kato T, Thie N, Montplaisir J, Lavigne GJ: Bruxism and orofacial movements during sleep. Dent Clin North Am 2001;45:657–684.
  14. Lavigne GJ, Manzini C: Sleep bruxism and concomitant motor activity; in Kryger MH, Roth T, Dement WC (eds): Principles and Practice of Sleep Medicine. Philadelphia, WB Saunders Co, 2000, pp 773–785.
  15. Macaluso GM, Guerra P, Di Giovanni G, Boselli M, Parrino L, Terzano MG: Sleep bruxism is a disorder related to periodic arousals during sleep. J Dent Res 1998;77:565–573.
  16. Kato T, Rompré PH, Montplaisir JY, Sessle BJ, Lavigne GJ: Sleep bruxism: An oromotor activity secondary to microarousal. J Dent Res 2001;80:1940–1944.
  17. Reding GR, Rubright WC, Zimmermann SO: Incidence of bruxism. J Dent Res 1966;45:1198–1204.
  18. Glaros AG: Incidence of diurnal and nocturnal bruxism. J Prosthet Dent 1981;45:545–549.
  19. Lavigne GJ, Montplaisir J: Restless legs syndrome and sleep bruxism: Prevalence and association among Canadians. Sleep 1994;17:739–743.
  20. Ohayon MM, Li KK, Guilleminault C: Risk factors for sleep bruxism in the general population. Chest 2001;119:53–61.
  21. Laberge L, Tremblay RE, Vitaro F, Montplaisir J: Development of parasomnias from childhood to early adolescence. Pediatrics 2000;106:67–74.
  22. Bader G, Lavigne GJ: Sleep bruxism: Overview of an oromandibular sleep movement disorder. Sleep Med Rev 2000;4:27–43.
  23. Johansson A, Haraldson T, Omar R, Kiliaridis S, Carlsson GE: A system for assessing the severity and progression of occlusal wear. J Oral Rehabil 1993;20:125–131.
  24. Lavigne GJ, Rompré PH, Montplaisir J: Sleep bruxism: Validity of clinical research diagnostic criteria in a controlled polysomnographic study. J Dent Res 1996;75:546–552.
  25. Kato T, Montplaisir J, Blanchet P, Lund JP, Lavigne GJ: Idiopathic myoclonus in the oromandibular region during sleep: A possible source of confusion in sleep bruxism diagnosis. Mov Disord 1999;14:865–871.
  26. Lavigne GJ, Rompré PH, Poirier G, Huard H, Kato T, Montplaisir JY: Rhythmic masticatory muscle activity during sleep in humans. J Dent Res 2001;80:443–448.
  27. Halasz P, Ujszaszi J, Gadoros J: Are microarousals preceded by electroencephalographic slow wave synchronization precursors of confusional awakenings? Sleep 1985;8:231–238.
  28. Saletu B, Saletu-Zyhlarz GM: Was Sie schon immer über Schlaf wissen wollten. Wien, Ueberreuter, 2001.
  29. Pierce CJ, Gale EN: A comparison on different treatments for nocturnal bruxism. J Dent Res 1988;67:597–601.
  30. Moss RA, Hammer D, Adams HE, Jenkins JO, Thompson K, Haber J: A more efficient biofeedback procedure for the treatment of nocturnal bruxism. J Oral Rehabil 1982;9:125–131.
  31. Clarke JH, Reynolds PJ: Suggestive hypnotherapy for nocturnal bruxism: A pilot study. Am J Clin Hypn 1991;33:248–253.
  32. Hudzinski LG, Walters PJ: Use of a portable electromyogram integrator and biofeedback unit in the treatment of chronic nocturnal bruxism. J Prosthet Dent 1987;58:698–701.
  33. Rugh JD, Johnson RW: Temporal analysis of nocturnal bruxism during EMG feedback. J Periodontol 1981;52:263–265.
  34. Solberg WK, Clark GT, Rugh JD: Nocturnal electromyographic evaluation of bruxism patients undergoing short term splint therapy. J Oral Rehabil 1975;2:215–223.
  35. Clark GT, Beemsterboer PL, Solberg WK, Rugh JD: Nocturnal electromygraphic evaluation of myofascial pain dysfunction in patients undergoing occlusal splint therapy. J Am Dent Assoc 1979;99:607–611.
  36. Okeson JP: The effects of hard and soft occlusal splints on nocturnal bruxism. J Am Dent Assoc 1987;114:788–791.
  37. Holmgren K, Sheikholeslam A, Riise C: Effect of a full-arch maxillary occlusal splint on parafunctional activity during sleep in patients with nocturnal bruxism and signs and symptoms of craniomandibular disorders. J Prosthet Dent 1993;69:293–297.
  38. Macaluso GM, Conversi G, Guerra P, Smerieri A, Boselli M, Parrino L, et al: Effect of splint therapy on sleep structure in bruxers. J Dent Res 1998;77:920.

    External Resources

  39. Dao TTT, Lavigne GJ: Oral splints: The crutches for temporomandibular disorders and bruxism? Crit Rev Oral Biol Med 1998;9:345–361.
  40. Yustin D, Neff P, Rieger MR, et al: Characterization of 86 bruxing patients and long term study of their management with occlusal devices and other forms of therapy. J Orofac Pain 1993;7:54–60.
  41. Ramfjord SP, Mich AA: Bruxism: A clinical and electromyographic study. J Am Dent Assoc 1961;62:35–58.
  42. Clark GT, Adler C: A critical evaluation of occlusal therapy: Occlusal adjustment procedures. J Am Dent Assoc 1985;110:743–750.
  43. Okeson JP: Orofacial Pain Guidelines for Assessment, Diagnosis, and Management. Carol Stream, Quintessence, 1996.
  44. Lavigne GJ, Montplaisir J: Bruxism: Epidemiology, diagnosis, pathophysiology, and pharmacology; in Friction JR, Dubner RB (eds): Advances in Pain Research and Therapy – Orofacial Pain and Temporomandibular Disorders. New York, Raven Press, 1995, pp 387–404.
  45. Dube C, Rompré PH, Manzini C, Guitard F, de Grandmont P, Lavigne GJ: Quantitative polygraphic controlled study on efficacy and safety of oral splint devices in tooth-grinding subjects. J Dent Res 2004;83:398–403.
  46. Oksenberg A, Arons E: Sleep bruxism related to obstructive sleep apnea: The effect of continous positive airway pressure. Sleep Med 2002;3513–515.
  47. Winocur E, Gavish A, Voikovitch M, Emodi-Perlman A, Eli I: Drugs and bruxism: A critical review. J Orofac Pain 2003;17:99–111.
  48. Hauer C, Saletu-Zyhlarz G, Mandl M, Saletu M, Piehslinger E, Saletu: Bruxismus-Diagnose und Therapie. Presented at the 41 Fachtagung für Neurophysiologie und angrenzende Gebiete, Champfer, Switzerland, 2002.
  49. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
  50. Zung W: A self-rating depression scale. Arch Gen Psychiatry 1965;12:63–70.
  51. Zung W: SAS, Self-Rating Anxiety Scale; in Guy W (ed): ECDEU Assessment Manual for Psychopharmacology. Rockville, US National Institute of Health, 1976, pp 337–340.
  52. Johns MW: A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 1991;14:540–545.
  53. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C: Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121–132.
  54. Mezzich JE, Ruiperez MA, Perez C, Yoon G, Liu J, Mahmud S: The Spanish version of the quality of life index: Presentation and validation. J Nerv Ment Dis 2000;188:301–305.
  55. Saletu B, Prause W, Löffler-Stastka H, Anderer P, Brandstätter N, Zoghlami A, Saletu-Zyhlarz G, Katschnig H: Quality of life in nonorganic and organic sleep disorders. 1. Comparison with normative data. Wien Klin Wochenschr 2003;115:246–254.
  56. Prause W, Saletu B, Anderer P, Gruber G, Löffler-Stastka H, Klösch G, Mandl M, Grätzhofer E, Saletu-Zyhlarz G, Katschnig H: Quality of life in nonorganic and organic sleep disorders. 2. Correlation with objective and subjective quality of sleep and awakening. Wien Klin Wochenschr 2003;115: 326–333.
  57. Sleep Disorders Atlas Task Force of the American Sleep Disorders Association: Recording and scoring leg movements. Sleep 1993;16:749–759.
  58. Sleep Disorders Atlas Task Force of the American Sleep Disorders Association: EEG arousals: Scoring rules and examples: A preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15:173–184.

    External Resources

  59. Rechtschaffen A, Kales A: A Manual of Standardized Terminology, Technique and Scoring System for Sleep Stages of Human Subjects. Los Angeles, University of California Brain Information Service, 1968.
  60. Saletu B, Wessely P, Grünberger J, Schultes M: Erste klinische Erfahrungen mit einem neuen schlafanstossenden Benzodiazepin, Cinolazepam, mittels eines Selbstbeurteilungsbogens für Schlaf- und Aufwachqualität (SSA). Neuropsychiatrie 1987;1:169–176.
  61. Saletu B, Anderer P, Frey R, Krupka M, Klösch G: Zur Neurophysiologie des Schlafes. Psychiatr Danub 1991;3:31–58.
  62. Von Zerssen D, Koeller DM, Rey ER: Die Befindlichkeits-Skala (Bf-S) – Ein einfaches Instrument zur Objektivierung von Befindlichkeits-Störungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneimittelforschung 1970;20:915–918.
  63. Grünberger J: Psychodiagnostik des Alkoholkranken. Ein methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Wien, Maudrich, 1977.
  64. Fünfgeld EW: Vigorimeter: Zur Kraftmessung der Hand und zur Simulationsprüfung. Dscht Med Wochenschr 1966;49:2214–2216.

    External Resources

  65. Benca RM, Obermeyer WH, Thisted RA, Gillin JC: Sleep and psychiatric disorders: A metaanalysis. Arch Gen Psychiatry 1992;49:651–668.
  66. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Semler B, Decker K, Parapatics S, Tschida U, Winkler A, Saletu B: Insomnia related to dysthymia: Comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology 2001;44:139–149.
  67. Saletu-Zyhlarz GM, Hassan Abu-Bakr M, Anderer P, Gruber G, Mandl M, Strobl R, Gollner D, Prause W, Saletu B: Insomnia in depression: Differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:249–260.
  68. Saletu M, Anderer P, Saletu B, Hauer C, Mandl M, Oberndorfer S, Zoghlami A, Saletu-Zyhlarz G: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000;41:190–199.
  69. Saletu M, Anderer P, Saletu B, Hauer C, Mandl M, Semler B, Saletu-Zyhlarz G: Sleep laboratory studies in periodic limb movement disorder (PLMD) as compared with normals and acute effects of ropinirole. Hum Psychopharmacol 2001;16:177–187.
  70. Saletu M, Anderer P, Saletu-Zyhlarz G, Prause W, Semler B, Zoghlami A, Gruber G, Hauer C, Saletu B: Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD). Acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol 2001;11:153–161.
  71. Saletu B, Gruber G, Saletu M, Brandstätter N, Hauer C, Prause W, Ritter K, Saletu-Zyhlarz G: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000;41:181–189.
  72. Lavigne GJ, Soucy J-P, Lobbezoo F, Manzini C, Blanchet PJ, Montplaisir JY: Double blind crossover, placebo-controlled trial with bromocriptine in patients with sleep bruxism. Clin Neuropharmacol 2001;4:145–149.
  73. Huynh NT, Lavigne GJ, Guitard F, Rompre PH, de Chaplain J, Montplaisir JY: Clonidine reduces sleep bruxism activity in a double-blind randomized crossover trial: Preliminary findings. 17th Congr Eur Sleep Res Soc, Prague, 2004.
  74. Abt K: Descriptive data analysis (DDA) in quantitative EEG studies; in Samson-Dollfus D, Guieu JD, Gotman J, Etevenon P (eds): Statistics and Topography in Quantitative EEG. Amsterdam, Elsevier, 1988, pp 150–160.
  75. Ferber G, Abt K, Fichte K, Luthringer R: IPEG guideline on statistical design and analysis for pharmacodynamic trials. Neuropsychobiology 1999;39:92–100.
  76. Saletu B, Anderer P, Saletu M, Hauer C, Lindeck-Pozza L, Saletu-Zyhlarz G: EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med 2002;3(suppl 1):S35–S42.

    External Resources

  77. Magee KR: Bruxism related to levodopa therapy. J Am Dent Assoc 1970;214:147.
  78. Lobbezoo F, Lavigne GJ, Tanguay R, et al: The effect of catecholamine precursor L-dopa on sleep bruxism: A controlled clinical trial. Mov Disord 1997;12:73–78.
  79. Micheli F, Pardal MF, Gatto M, et al: Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmacol 1993;16:315–323.
  80. Amir I, Hermesh H, Gavish A: Bruxism secondary to antipsychotic drug exposure: A positive response to propanolol. Clin Neuropharmacol 1997;20:86–89.
  81. Ellison JA, Stanziani P: SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993;54:432–434.
  82. Por CH, Watson L, Doucette D, et al: Sertraline-associated bruxism. Can J Clin Pharmacol 1996;3:123–125.
  83. Gerber PE, Lynd LD: Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32:692–698.
  84. Etzel KR, Stockstill JW, Rugh JD, et al: Tryptophan supplementation for nocturnal bruxism. Report of negative results. J Craniomandib Disord 1991;5:115–119.
  85. Mohamed SE, Christensen LV, Penchas J: A randomized double-blind clinical trial of the effect of amitriptyline on nocturnal masseteric motor activity (sleep bruxism). Cranio 1997;15:326–332.
  86. Raigrodski A, Christensen L, Mohamed S, Gardiner D: The effect of a 4-week administration of amitriptylin on sleep bruxism. A double-blind crossover clinical study. Cranio 2001;19:21–25.
  87. Lobbezoo F, Naeije M: Bruxism is mainly regulated centrally, not peripherally. J Oral Rehabil 2001;12:1085–1091.

 goto top of outline Author Contacts

Univ. Ass. DDr. Alexander Saletu, MD, Clinic of Dentistry
Department of Periodontology, Medical University of Vienna
Währinger Strasse 25a, AT–1090 Vienna (Austria)
Tel. +43 1 42 77 67 211, Fax +43 1 42 77 67 205

 goto top of outline Article Information

Published online: May 23, 2005
Number of Print Pages : 12
Number of Figures : 3, Number of Tables : 7, Number of References : 87

 goto top of outline Publication Details

Neuropsychobiology (International Journal of Experimental and Clinical Research in Biological Psychiatry, Pharmacopsychiatry, Biological Psychology/Pharmacopsychology and Pharmacoelectroencephalography)

Vol. 51, No. 4, Year 2005 (Cover Date: Released June 2005)

Journal Editor: Strik, W. (Bern)
ISSN: 0302–282X (print), 1423–0224 (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.